[go: up one dir, main page]

CN1323210A - 治疗精神分裂症的方法及应用该方法的装置 - Google Patents

治疗精神分裂症的方法及应用该方法的装置 Download PDF

Info

Publication number
CN1323210A
CN1323210A CN99812210A CN99812210A CN1323210A CN 1323210 A CN1323210 A CN 1323210A CN 99812210 A CN99812210 A CN 99812210A CN 99812210 A CN99812210 A CN 99812210A CN 1323210 A CN1323210 A CN 1323210A
Authority
CN
China
Prior art keywords
nicotine
officinal salt
treatment device
medical treatment
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN99812210A
Other languages
English (en)
Chinese (zh)
Inventor
R·麦考尼
V·西姆德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LTS Lohmann Therapie Systeme AG
Original Assignee
LTS Lohmann Therapie Systeme AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LTS Lohmann Therapie Systeme AG filed Critical LTS Lohmann Therapie Systeme AG
Publication of CN1323210A publication Critical patent/CN1323210A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN99812210A 1998-10-16 1999-10-02 治疗精神分裂症的方法及应用该方法的装置 Pending CN1323210A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19847715.5 1998-10-16
DE19847715A DE19847715A1 (de) 1998-10-16 1998-10-16 Verfahren zur Behandlung der Schizophrenie sowie Mittel zur Verwendung in diesem Verfahren

Publications (1)

Publication Number Publication Date
CN1323210A true CN1323210A (zh) 2001-11-21

Family

ID=7884666

Family Applications (1)

Application Number Title Priority Date Filing Date
CN99812210A Pending CN1323210A (zh) 1998-10-16 1999-10-02 治疗精神分裂症的方法及应用该方法的装置

Country Status (10)

Country Link
EP (1) EP1121126A1 (pt)
JP (1) JP2002527478A (pt)
KR (1) KR20010080135A (pt)
CN (1) CN1323210A (pt)
AR (1) AR020815A1 (pt)
AU (1) AU6199299A (pt)
BR (1) BR9914570A (pt)
CA (1) CA2341855A1 (pt)
DE (1) DE19847715A1 (pt)
WO (1) WO2000023077A1 (pt)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1907273B (zh) * 2005-08-01 2011-12-28 日东电工株式会社 烟碱透皮制剂的制备方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10110953A1 (de) * 2001-03-07 2002-09-19 Lohmann Therapie Syst Lts Transdermales therapeutisches System zur Verabreichung von partiellen Dopamin-D2-Agonisten
KR20060120156A (ko) * 2003-10-28 2006-11-24 알자 코포레이션 담배의 이용빈도를 감소시키기 위한 방법 및 장치
US20140155429A1 (en) * 2011-05-09 2014-06-05 Envivo Pharmaceuticals, Inc. Treatment of Cognitive Disorders with Certain Alpha-7 Nicotinic Acid Receptor Agonists in Combination with Nicotine
CZ309812B6 (cs) * 2021-05-25 2023-11-01 Consumer Brands International s.r.o Směs pro výrobu nikotinových sáčků a způsob její výroby

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680172A (en) * 1985-03-05 1987-07-14 Ciba-Geigy Corporation Devices and methods for treating memory impairment
US4915950A (en) * 1988-02-12 1990-04-10 Cygnus Research Corporation Printed transdermal drug delivery device
GB9614902D0 (en) * 1996-07-16 1996-09-04 Rhodes John Sustained release composition
US5776956A (en) * 1996-07-30 1998-07-07 Lectec Corporation Use of cotinine in treating psychiatric disorders
US5776957A (en) * 1996-11-15 1998-07-07 The University Of Kentucky Research Foundation Nornicotine enantiomers for use as a treatment for dopamine related conditions and disease states

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1907273B (zh) * 2005-08-01 2011-12-28 日东电工株式会社 烟碱透皮制剂的制备方法

Also Published As

Publication number Publication date
DE19847715A1 (de) 2000-04-20
KR20010080135A (ko) 2001-08-22
CA2341855A1 (en) 2000-04-27
BR9914570A (pt) 2001-07-03
EP1121126A1 (de) 2001-08-08
WO2000023077A1 (de) 2000-04-27
AR020815A1 (es) 2002-05-29
AU6199299A (en) 2000-05-08
JP2002527478A (ja) 2002-08-27

Similar Documents

Publication Publication Date Title
US11471424B2 (en) Biosynchronous transdermal drug delivery
Lehmann et al. Transdermal fentanyl: clinical pharmacology
AU660336B2 (en) Device for the transdermal administration of melatonin
JP2009544619A5 (pt)
NO20110342L (no) Fentanylpreparat for nasal administrering
KR100601901B1 (ko) 흡연자 중독치료용의 활성 물질을 조합한 니코틴 함유 경피 또는 경점막 투여 약학 제형
JP2013516482A (ja) 局所経皮用デクスメデトミジン組成物およびそれらの使用方法
AU2010282660B2 (en) Methods for iontophoretically treating nausea and migraine
ZA200706640B (en) Method for a treatment with a medicament combination and medicament combinations suitable for the same
CN1323210A (zh) 治疗精神分裂症的方法及应用该方法的装置
US20150352038A1 (en) A dosage form for administering an active principle for accelerated sleep induction and/or for treating sleep disorders and/or for treating a central nervous system disorder
Stanley Anesthesia for the 21st century
JP2003176227A (ja) 製薬組成物、喫煙を控えている患者の喫煙禁断症状を軽減する方法及び患者の喫煙禁断症状を軽減するキット
WO2018071656A1 (en) Formulations for treatment of migraines
CN1067875C (zh) 雌二醇周效透皮吸收贴片
CN1226163A (zh) 治疗和/或预防痴呆的制剂
WO2021011597A1 (en) Pharmaceutical formulations containing gaboxadol for therapeutic treatment
CA2547873A1 (en) Tetrapeptide regulating blood glucose level in diabetes mellitus
Zech et al. Transdermal (TTS) fentanyl in cancer pain management
CN1037405C (zh) 咽喉部喷射药膜
US11364228B2 (en) Gaboxadol for therapeutic treatment of 1p36 deletion syndrome
CN112891379A (zh) 一种用于婴幼儿鹅口疮的药物组合物及其应用
TRADE llBRIllM'
De La Harpe A comparison of the efficacy and safety of intranasal sufentanil/midazolam and ketamine/midazolam for sedation and analgesia in a paediatric population undergoing multiple dental extractions
Dose et al. ium, high doses of beta-receptor blocking agents or anti

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication